We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

115 hedge funds and large institutions have $482M invested in Karyopharm Therapeutics in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 49 increasing their positions, 34 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 34

0.88% more ownership

Funds ownership: 4.77% → 5.65% (+0.88%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3% less funds holding

Funds holding: 119 → 115 (-4)

12% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 17

35% less capital invested

Capital invested by funds: $738M → $482M (-$256M)

38% less call options, than puts

Call options by funds: $553K | Put options by funds: $894K

Holders
115
Holders Change
-4
Holders Change %
-3.36%
% of All Funds
2.56%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
49
Reduced
34
Closed
17
Calls
$553K
Puts
$894K
Net Calls
-$341K
Net Calls Change
+$2.08M

Top Buyers

Rank Fund Capital Flow
1
EA
Emerald Advisers
Pennsylvania
+$8.57M
2
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
+$8.17M
3
CS
Candriam SCA
Luxembourg
+$7.95M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$7.77M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.17M

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$7.69M
2
Millennium Management
Millennium Management
New York
-$4.37M
3
SSA
Schonfeld Strategic Advisors
New York
-$3.32M
4
DAM
Doheny Asset Management
California
-$1.89M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$1.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
26
Federated Hermes
Pennsylvania
$2.75M -$27.7K -164 -0.8%
Charles Schwab
27
Charles Schwab
California
$2.52M -$35.4K -210 -1%
Citadel Advisors
28
Citadel Advisors
Florida
$2.36M +$123K +731 +5%
Two Sigma Advisers
29
Two Sigma Advisers
New York
$2.19M -$55K -326 -2%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$2.05M -$2.02K -12 -0.1%
UBS Group
31
UBS Group
Switzerland
$2.03M +$2.28M +13,497 +1,416%
SIM
32
Spark Investment Management
New York
$1.63M +$1.26M +7,451 +180%
FMBTD
33
First Midwest Bank Trust Division
Illinois
$1.59M +$1.91M +11,339 New
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$1.59M -$603K -3,573 -24%
First Trust Advisors
35
First Trust Advisors
Illinois
$1.58M +$1.89M +11,211 New
FCM
36
Frontier Capital Management
Massachusetts
$1.55M -$435K -2,577 -19%
California Public Employees Retirement System
37
California Public Employees Retirement System
California
$1.55M +$1.48M +8,799 +391%
Goldman Sachs
38
Goldman Sachs
New York
$1.51M -$1.33M -7,864 -42%
CIA
39
Capital Impact Advisors
Massachusetts
$1.4M +$579K +3,430 +50%
MOACM
40
Mutual of America Capital Management
New York
$1.27M – – –
Citigroup
41
Citigroup
New York
$1.23M +$1.35M +8,009 +1,125%
SSA
42
Schonfeld Strategic Advisors
New York
$1.15M -$3.32M -19,686 -71%
JP Morgan Chase
43
JP Morgan Chase
New York
$1.1M -$48.9K -290 -4%
Allianz Asset Management
44
Allianz Asset Management
Germany
$1.03M +$20.2K +120 +2%
USAA
45
United Services Automobile Association
Texas
$1.01M -$60.7K -360 -5%
PAM
46
Panagora Asset Management
Massachusetts
$946K -$47.7K -283 -4%
MCM
47
Moore Capital Management
New York
$937K – – –
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$879K +$575K +3,411 +120%
Morgan Stanley
49
Morgan Stanley
New York
$804K -$150K -889 -13%
Swiss National Bank
50
Swiss National Bank
Switzerland
$798K – – –
1
2
3 4 5

KPTI Hedge Fund Activity: Q4 2018 in Review

115 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2018, worth a combined $482M — down 35% from $738M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of KPTI and 15 opened new positions — a net loss of 2 holders — while 34 trimmed existing stakes and 49 added.

The largest buyer was Emerald Advisers, adding an estimated $8.57M. The largest seller was Vanguard Group, cutting an estimated $7.69M.

  • 115 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2018, down from 119 in Q3 2018.
  • Funds reported $482M of Karyopharm Therapeutics stock for Q4 2018, down 35% quarter-over-quarter.
  • 15 funds opened new Karyopharm Therapeutics positions in Q4 2018 and 17 closed out, a net change of -2 holders.
  • The largest Karyopharm Therapeutics buyer in Q4 2018 was Emerald Advisers, an estimated $8.57M added.
  • The largest Karyopharm Therapeutics seller in Q4 2018 was Vanguard Group, an estimated $7.69M sold.

Based on aggregated 13F filings for Q4 2018.